| Stage | ABT | % of rev | JNJ | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $12.6B | 100.00% | $25.4B | 100.00% | JNJ ×2.02 |
| Gross profit | $7.3B | 57.71% | $17.3B | 68.12% | JNJ +10.4pp |
| Operating income | $1.7B | 13.44% | $5.8B | 23.01% | JNJ +9.6pp |
| Pre-tax income | $1.5B | 12.10% | $34M | 0.13% | ABT +12.0pp |
| Net income | $928M | 7.37% | $210M | 0.83% | ABT +6.5pp |
| Stage | ABT | JNJ | Gap · A − B |
|---|---|---|---|
| Revenue | $12.6B100.00% | $25.4B100.00% | JNJ ×2.02 |
| Gross profit | 57.71%$7.3B | 68.12%$17.3B | JNJ +10.4pp |
| Operating income | 13.44%$1.7B | 23.01%$5.8B | JNJ +9.6pp |
| Pre-tax income | 12.10%$1.5B | 0.13%$34M | ABT +12.0pp |
| Net income |
| 7.37%$928M |
| 0.83%$210M |
| ABT +6.5pp |
ABT · GPK 10-KMar 2 '26
“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.”
JNJ · GPK 10-KMar 2 '26
“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.”